vs

Side-by-side financial comparison of Ispire Technology Inc. (ISPR) and Entrada Therapeutics, Inc. (TRDA). Click either name above to swap in a different company.

Entrada Therapeutics, Inc. is the larger business by last-quarter revenue ($20.6M vs $20.3M, roughly 1.0× Ispire Technology Inc.). Ispire Technology Inc. runs the higher net margin — -32.5% vs -84.4%, a 51.8% gap on every dollar of revenue. On growth, Ispire Technology Inc. posted the faster year-over-year revenue change (-51.5% vs -65.2%). Ispire Technology Inc. produced more free cash flow last quarter ($-4.0M vs $-39.7M). Over the past eight quarters, Entrada Therapeutics, Inc.'s revenue compounded faster (6.4% CAGR vs -17.8%).

Ispire Technology Inc. is a global tech firm specializing in R&D, manufacturing and sales of advanced vaporization hardware and supporting consumables. It serves nicotine and legal cannabis consumer markets, operates two core segments of hardware and branded cannabis products, covers North America, Europe and Asia-Pacific, delivering compliant innovative vapor solutions for B2B partners and end users.

Entrada Therapeutics is a clinical-stage biotechnology firm developing transformative intracellular therapies for serious rare diseases and high-unmet-need disorders. Its pipeline covers neuromuscular, metabolic, and central nervous system segments, serving global patients via healthcare partnerships.

ISPR vs TRDA — Head-to-Head

Bigger by revenue
TRDA
TRDA
1.0× larger
TRDA
$20.6M
$20.3M
ISPR
Growing faster (revenue YoY)
ISPR
ISPR
+13.7% gap
ISPR
-51.5%
-65.2%
TRDA
Higher net margin
ISPR
ISPR
51.8% more per $
ISPR
-32.5%
-84.4%
TRDA
More free cash flow
ISPR
ISPR
$35.6M more FCF
ISPR
$-4.0M
$-39.7M
TRDA
Faster 2-yr revenue CAGR
TRDA
TRDA
Annualised
TRDA
6.4%
-17.8%
ISPR

Income Statement — Q2 FY2026 vs Q1 FY2025

Metric
ISPR
ISPR
TRDA
TRDA
Revenue
$20.3M
$20.6M
Net Profit
$-6.6M
$-17.3M
Gross Margin
17.1%
Operating Margin
-33.9%
-106.0%
Net Margin
-32.5%
-84.4%
Revenue YoY
-51.5%
-65.2%
Net Profit YoY
17.4%
-173.8%
EPS (diluted)
$-0.12
$-0.42

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ISPR
ISPR
TRDA
TRDA
Q4 25
$20.3M
Q3 25
$30.4M
Q2 25
$20.1M
Q1 25
$26.2M
$20.6M
Q4 24
$41.8M
$37.4M
Q3 24
$39.3M
$19.6M
Q2 24
$37.3M
$94.7M
Q1 24
$30.0M
$59.1M
Net Profit
ISPR
ISPR
TRDA
TRDA
Q4 25
$-6.6M
Q3 25
$-3.3M
Q2 25
$-14.8M
Q1 25
$-10.9M
$-17.3M
Q4 24
$-8.0M
$1.1M
Q3 24
$-5.6M
$-14.0M
Q2 24
$-3.5M
$55.0M
Q1 24
$-5.9M
$23.5M
Gross Margin
ISPR
ISPR
TRDA
TRDA
Q4 25
17.1%
Q3 25
17.0%
Q2 25
12.3%
Q1 25
18.2%
Q4 24
18.5%
Q3 24
19.5%
Q2 24
28.3%
Q1 24
20.4%
Operating Margin
ISPR
ISPR
TRDA
TRDA
Q4 25
-33.9%
Q3 25
-8.9%
Q2 25
-72.7%
Q1 25
-40.4%
-106.0%
Q4 24
-17.6%
-15.7%
Q3 24
-13.4%
-110.7%
Q2 24
-9.2%
56.4%
Q1 24
-18.8%
35.7%
Net Margin
ISPR
ISPR
TRDA
TRDA
Q4 25
-32.5%
Q3 25
-10.7%
Q2 25
-73.4%
Q1 25
-41.5%
-84.4%
Q4 24
-19.1%
3.0%
Q3 24
-14.2%
-71.7%
Q2 24
-9.4%
58.1%
Q1 24
-19.7%
39.7%
EPS (diluted)
ISPR
ISPR
TRDA
TRDA
Q4 25
$-0.12
Q3 25
$-0.06
Q2 25
$-0.26
Q1 25
$-0.19
$-0.42
Q4 24
$-0.14
$-0.20
Q3 24
$-0.10
$-0.35
Q2 24
$-0.07
$1.55
Q1 24
$-0.11
$0.68

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ISPR
ISPR
TRDA
TRDA
Cash + ST InvestmentsLiquidity on hand
$17.6M
$67.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$-7.7M
$417.3M
Total Assets
$84.4M
$486.5M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ISPR
ISPR
TRDA
TRDA
Q4 25
$17.6M
Q3 25
$22.7M
Q2 25
$24.4M
Q1 25
$23.5M
$67.8M
Q4 24
$34.4M
$101.2M
Q3 24
$37.7M
$78.0M
Q2 24
$35.1M
$185.3M
Q1 24
$39.5M
$68.4M
Stockholders' Equity
ISPR
ISPR
TRDA
TRDA
Q4 25
$-7.7M
Q3 25
$-1.8M
Q2 25
$604.7K
Q1 25
$14.8M
$417.3M
Q4 24
$24.2M
$428.7M
Q3 24
$30.7M
$422.4M
Q2 24
$34.5M
$429.9M
Q1 24
$35.9M
$269.4M
Total Assets
ISPR
ISPR
TRDA
TRDA
Q4 25
$84.4M
Q3 25
$96.4M
Q2 25
$102.2M
Q1 25
$115.7M
$486.5M
Q4 24
$132.0M
$526.3M
Q3 24
$129.0M
$554.6M
Q2 24
$122.6M
$582.0M
Q1 24
$108.0M
$510.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ISPR
ISPR
TRDA
TRDA
Operating Cash FlowLast quarter
$-4.0M
$-38.5M
Free Cash FlowOCF − Capex
$-4.0M
$-39.7M
FCF MarginFCF / Revenue
-19.9%
-192.9%
Capex IntensityCapex / Revenue
0.3%
5.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-14.2M
$-58.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ISPR
ISPR
TRDA
TRDA
Q4 25
$-4.0M
Q3 25
$-1.2M
Q2 25
$4.7M
Q1 25
$-12.5M
$-38.5M
Q4 24
$-3.2M
$-31.6M
Q3 24
$3.6M
$-24.3M
Q2 24
$-1.4M
$39.8M
Q1 24
$3.4M
$-25.5M
Free Cash Flow
ISPR
ISPR
TRDA
TRDA
Q4 25
$-4.0M
Q3 25
$-1.2M
Q2 25
$3.7M
Q1 25
$-12.7M
$-39.7M
Q4 24
$-3.2M
$-32.2M
Q3 24
$3.3M
$-24.9M
Q2 24
$-2.2M
$38.8M
Q1 24
$3.3M
$-26.4M
FCF Margin
ISPR
ISPR
TRDA
TRDA
Q4 25
-19.9%
Q3 25
-3.9%
Q2 25
18.6%
Q1 25
-48.4%
-192.9%
Q4 24
-7.7%
-86.2%
Q3 24
8.5%
-127.3%
Q2 24
-5.9%
41.0%
Q1 24
10.9%
-44.6%
Capex Intensity
ISPR
ISPR
TRDA
TRDA
Q4 25
0.3%
Q3 25
0.0%
Q2 25
4.8%
Q1 25
0.7%
5.6%
Q4 24
0.1%
1.7%
Q3 24
0.7%
3.3%
Q2 24
2.0%
1.1%
Q1 24
0.3%
1.4%
Cash Conversion
ISPR
ISPR
TRDA
TRDA
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
-27.94×
Q3 24
Q2 24
0.72×
Q1 24
-1.09×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons